Cardiorenal protective effect of sodium-glucose cotransporter 2 inhibitors and mitochondrial function

J Diabetes Investig. 2019 May;10(3):557-559. doi: 10.1111/jdi.12987. Epub 2019 Jan 23.

Abstract

Cardiorenal protective effects of sodium–glucose cotransporter 2 inhibitors are difficult to explain. From the recent works by Takagi et al. and an expert consensus report, I suggest further works on the effects of sodium–glucose cotransporter 2inhibitors on mitochondrial function could help to understand this very interesting development.

Publication types

  • Editorial

MeSH terms

  • Clinical Trials as Topic
  • Heart Failure / prevention & control*
  • Humans
  • Kidney Diseases / drug therapy*
  • Mitochondria / drug effects*
  • Protective Agents / therapeutic use*
  • Sodium-Glucose Transporter 2 Inhibitors / administration & dosage*
  • Treatment Outcome

Substances

  • Protective Agents
  • Sodium-Glucose Transporter 2 Inhibitors